Apr 14, 2025, 11:52

The AACR-ALK Positive Lung Cancer Research Fellowship

The AACR-ALK Positive Lung Cancer Research Fellowship is a two-year grant designed to support a postdoctoral or clinical research fellow working on a mentored project directly relevant to ALK-positive non-small cell lung cancer. This program encourages innovative research in basic, clinical, translational, or population sciences to help establish the recipient’s career in the field of lung cancer.

Eligibility Criteria:

Must hold a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field.
Must not be a candidate for another doctoral degree.
Must hold a mentored research position (postdoctoral fellow, clinical research fellow, or equivalent) by September 1, 2025.
Doctoral degree or medical residency must have been completed within the past 5 years (not before September 1, 2020).
Must work under a mentor at an academic, medical, or research institution.
No citizenship or geographic restrictions (visa status must allow completion of project at host institution).
Must be an AACR member in good standing or submit a satisfactory membership application by the deadline.

Funding Details:

Amount: 130,000 USD total.
Duration: 2 years.
Use of Funds: Salary, benefits, and research-related expenses (excluding clinical compensation and indirect costs).

Deadline:

Application Due: May 15, 2025 at 1:00 PM U.S. Eastern Time.
Start of Grant Term: September 1, 2025.
Decision Date: July 2025.

Further Information:

Apply via ProposalCentral.
For membership inquiries: [email protected].
For application assistance: [email protected].

AACR AACR grants ALK-positive lung cancer cancer cancer fellowship cancer mentorship cancer research funding clinical research fellow immunotherapy research lung cancer research non small cell lung cancer OncoDaily Oncology oncology fellowship postdoctoral research targeted therapies Translational Oncology

Douglas Flora: Fighting Cancer with Heart

Eric Small: Deeply Honored to Step Into the Role of 2025-26 ASCO President

Cyril Konto: I Trademarked The Word ‘Multispecific’ The Day I Arrived

Levi Garraway: Transforming Oncology Through Precision, Resilience And Heart

20 Posts Not to Miss from ASCO 2025